We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Levels of Raltegravir in the Female Genital Tissue

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01327482
First Posted: April 1, 2011
Last Update Posted: December 19, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Caroline Mitchell, University of Washington
Results First Submitted: December 10, 2014  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label)
Condition: HIV
Intervention: Drug: Raltegravir

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Raltegravir Healthy volunteers who had regular menses and were not on hormonal contraception

Participant Flow:   Overall Study
    Raltegravir
STARTED   10 
COMPLETED   9 [1] 
NOT COMPLETED   1 
Adverse Event                1 
[1] The 10th participant completed 2/3 visits



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Raltegravir Healthy volunteers who had regular menses and were not on hormonal contraception

Baseline Measures
   Raltegravir 
Overall Participants Analyzed 
[Units: Participants]
 10 
Age 
[Units: Years]
Mean (Standard Deviation)
 30  (8) 
Gender 
[Units: Participants]
 
Female   10 
Male   0 
Region of Enrollment 
[Units: Participants]
 
United States   10 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Tissue Raltegravir Concentrations   [ Time Frame: 7, 14, 21 days ]

2.  Secondary:   Plasma Raltegravir Concentrations   [ Time Frame: 7, 14, 21 days ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Caroline Mitchell
Organization: Massachusetts General Hospital
phone: 617-724-2182
e-mail: caroline.mitchell@mgh.harvard.edu



Responsible Party: Caroline Mitchell, University of Washington
ClinicalTrials.gov Identifier: NCT01327482     History of Changes
Other Study ID Numbers: 38681-D
First Submitted: March 30, 2011
First Posted: April 1, 2011
Results First Submitted: December 10, 2014
Results First Posted: December 19, 2014
Last Update Posted: December 19, 2014